Clearbridge Investments LLC Acquires 1,479 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Clearbridge Investments LLC increased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.5% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 44,321 shares of the company’s stock after buying an additional 1,479 shares during the quarter. Clearbridge Investments LLC owned 0.05% of IDEXX Laboratories worth $23,930,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of IDXX. Nordea Investment Management AB lifted its holdings in shares of IDEXX Laboratories by 15.5% in the first quarter. Nordea Investment Management AB now owns 13,719 shares of the company’s stock worth $7,447,000 after acquiring an additional 1,839 shares during the last quarter. Brevan Howard Capital Management LP bought a new position in IDEXX Laboratories in the 4th quarter valued at approximately $3,183,000. Assenagon Asset Management S.A. lifted its stake in IDEXX Laboratories by 25.4% in the 4th quarter. Assenagon Asset Management S.A. now owns 43,593 shares of the company’s stock valued at $24,196,000 after purchasing an additional 8,831 shares during the last quarter. Carderock Capital Management Inc. boosted its position in IDEXX Laboratories by 35.7% in the fourth quarter. Carderock Capital Management Inc. now owns 16,416 shares of the company’s stock valued at $9,112,000 after buying an additional 4,315 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale grew its stake in shares of IDEXX Laboratories by 9.4% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 42,045 shares of the company’s stock worth $23,307,000 after buying an additional 3,627 shares during the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at IDEXX Laboratories

In other news, Director Bruce L. Claflin sold 200 shares of the company’s stock in a transaction on Friday, May 17th. The shares were sold at an average price of $540.80, for a total value of $108,160.00. Following the completion of the sale, the director now owns 161 shares in the company, valued at approximately $87,068.80. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 2.11% of the company’s stock.

IDEXX Laboratories Trading Up 0.2 %

IDEXX Laboratories stock traded up $0.93 during trading hours on Wednesday, reaching $471.34. 656,892 shares of the company’s stock were exchanged, compared to its average volume of 475,404. The firm has a market capitalization of $38.93 billion, a PE ratio of 45.63, a PEG ratio of 3.89 and a beta of 1.32. The firm’s 50 day simple moving average is $498.03 and its 200 day simple moving average is $518.59. The company has a quick ratio of 1.16, a current ratio of 1.57 and a debt-to-equity ratio of 0.40. IDEXX Laboratories, Inc. has a twelve month low of $372.50 and a twelve month high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Wednesday, May 1st. The company reported $2.81 EPS for the quarter, beating analysts’ consensus estimates of $2.68 by $0.13. IDEXX Laboratories had a return on equity of 63.66% and a net margin of 23.26%. The business had revenue of $964.10 million during the quarter, compared to analyst estimates of $965.43 million. Research analysts predict that IDEXX Laboratories, Inc. will post 11 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on IDXX. William Blair reiterated an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. Stifel Nicolaus cut their price target on IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating on the stock in a research note on Monday, June 24th. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, July 10th. Morgan Stanley dropped their price objective on shares of IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating for the company in a report on Tuesday, May 14th. Finally, Barclays cut their target price on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a research report on Thursday, May 2nd. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $586.63.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.